更新于：2024-11-12
Tinidazole
替硝唑
更新于：2024-11-12
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C8H13N3O4S |
InChIKeyHJLSLZFTEKNLFI-UHFFFAOYSA-N |
CAS号19387-91-8 |
关联
45
项与 替硝唑 相关的临床试验Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis
Porphyromonas Gingivalis Elimination From Oral Improves Esophageal Cancer Patients Survival After Radical Operation
Fasted-state in vivo bioequivalence study of Tinidazole 500 mg tablet
100 项与 替硝唑 相关的临床结果
登录后查看更多信息
100 项与 替硝唑 相关的转化医学
登录后查看更多信息
100 项与 替硝唑 相关的专利（医药）
登录后查看更多信息
1,516
项与 替硝唑 相关的文献（医药）2024-11-01Fresenius Zeitschrift für Analytische Chemie
Development of purity certified reference materials to establish metrological traceability for the measurement of nitroimidazoles in agricultural products
Article
作者: Zhang, LiYuan ; Zhou, Jian ; Liu, QingYi ; Li, FuKai ; Yang, MengRui ; Wang, Min ; Jiang, Bin
It is of significant importance to public health that reliable monitoring of nitroimidazoles be conducted, while certified reference materials (CRMs) are essential for accurate and reliable detection. A project has been initiated with the objective of developing nitroimidazole purity CRMs to ensure that results from nationwide monitoring laboratories for nitroimidazoles in antibiotic residues can be compared and traced. The candidates were successively characterized in terms of their structure by means of infrared (IR) spectroscopy and mass spectrometry (MS). The mass balance (MB) method and the quantitative nuclear magnetic resonance (qNMR) method were utilized to determine the purity of nitroimidazoles with remarkable accuracy. Furthermore, a methodical investigation was conducted on homogeneity, stability, and uncertainty. Six nitroimidazole purity CRMs, including tinidazole (GBW09252), secnidazole (GBW09286), ronidazole (GBW09288), metronidazole (GBW(E)090755), dimetridazole (GBW(E)090819), and ornidazole (GBW(E)090820), were finally manufactured following authorization from China's State Administration for Market Regulation (SAMR). By using these CRMs, it is possible to improve the traceability, accuracy, and comparability of nitroimidazole measurements in a range of agricultural products, protecting public health.
2024-11-01ULTRASONICS SONOCHEMISTRY
Ultrasonically assisted fabrication of electrochemical platform for tinidazole detection
Article
作者: Cui, Wenyu ; Zhang, Chaojun ; Yang, Wein-Duo ; Liu, Rijia ; Liu, Rui ; Sun, Yuan
Based on sonochemistry, green synthesis methods play an important role in the development of nanomaterials. In this work, a novel chitosan modified MnMoO4/g-C3N4 (MnMoO4/g-C3N4/CHIT) was developed using ultrasonic cell disruptor (500 W, 30 kHz) for ultra-sensitive electrochemical detection of tinidazole (TNZ) in the environment. The morphology and surface properties of the synthesized MnMoO4/g-C3N4/CHIT electrode were characterized using X-ray diffraction (XRD), fourier transform infrared spectroscopy (FT-IR), scanning electron microscope (SEM) and transmission electron microscope (TEM). Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques were utilized to assess the electrochemical performance of TNZ. The results indicate that the electrochemical detection performance of TNZ is highly efficient, with a detection limit (LOD) of 3.78 nM, sensitivity of 1.320 µA·µM-1·cm-2, and a detection range of 0.1-200 μM. Additionally, the prepared electrode exhibits excellent selectivity, desirable anti-interference capability, and decent stability. MnMoO4/g-C3N4/CHIT can be successfully employed to detect TNZ in both the Songhua River and tap water, achieving good recovery rates within the range of 93.0 % to 106.6 %. Consequently, MnMoO4/g-C3N4/CHIT's simple synthesis might provide a new electrode for the sensitive, repeatable, and selective measurement of TNZ in real-time applications. Using the MnMoO4/g-C3N4/CHIT electrode can effectively monitor and detect the concentration of TNZ in environmental water, guiding the sewage treatment process and reducing the pollution level of antibiotics in the water environment.
2024-11-01ADVANCED MATERIALS
Ultrasound‐Activated Probiotics Vesicles Coating for Titanium Implant Infections Through Bacterial Cuproptosis‐Like Death and Immunoregulation
Article
作者: Yue, Yan ; Wang, Wenqi ; Li, Shuoyuan ; Cheng, Lei ; Zhou, Zongke ; Li, Qiaochu ; Li, Jiyao ; Chen, Xiaoting ; Han, Mingyue ; Yang, Jiaojiao ; Zhang, Yangming ; Li, Jianshu ; Wang, Duan ; Cao, Jian ; Wan, Xufeng
Abstract:
Implant‐associated infections (IAIs) are the main cause of prosthetic implant failure. Bacterial biofilms prevent antibiotic penetration, and the unique metabolic conditions in hypoxic biofilm microenvironment may limit the efficacy of conventional antibiotic treatment. Escaping survival bacteria may not be continually eradicated, resulting in the recurrence of IAIs. Herein, a sonosensitive metal‐organic framework of Cu‐TCPP (tetrakis(4‐carboxyphenyl) porphyrin) nanosheets and tinidazole doped probiotic‐derived membrane vesicles (OMVs) with high‐penetration sonodynamic therapy (SDT), bacterial metabolic state interference, and bacterial cuproptosis‐like death to eradicate IAIs is proposed. The Cu‐TCPP can convert O2 to toxic 1O2 through SDT in the normoxic conditions, enhancing the hypoxic microenvironment and activating the antibacterial activity of tinidazole. The released Cu(II) under ultrasound can be converted to Cu(I) by exogenous poly(tannic acid) (pTA) and endogenous glutathione. The disruption of the bacterial membrane by SDT can enhance the Cu(I) transporter activity. Transcriptomics indicate that the SDT‐enhanced Cu(I) overload and hypoxia‐activated therapy hinder the tricarboxylic acid cycle (TCA), leading to bacterial cuproptosis‐like death. Moreover, the OMVs‐activated therapy can polarize macrophages to a M2‐like phenotype and facilitate bone repair. The sonodynamic biofilm microenvironment modulation strategy, whereby the hypoxia‐enhanced microenvironment is potentiated to synergize SDT with OMVs‐activated therapy, provides an effective strategy for antibacterial and osteogenesis performance.
100 项与 替硝唑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌性阴道炎 | 美国 | 2007-05-21 | |
| 阿米巴病 | 美国 | 2004-05-17 | |
| 贾第虫病 | 美国 | 2004-05-17 | |
| 滴虫感染 | 美国 | 2004-05-17 | |
| 细菌感染 | 中国 | 1994-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 593 | (Tinidazole 1 gm) | 襯餘窪築繭繭鬱憲鏇壓(獵窪鹽鹹觸餘鹽餘獵糧) = 繭淵夢獵鏇鑰鏇獵鹽壓 襯窪糧繭夢鹹願壓憲獵 (壓糧遞簾淵獵積製鑰夢, 鏇願範膚範遞鹽窪製壓 ~ 壓齋襯糧繭網蓋廠築繭) 更多 | - | 2011-06-23 | ||
(Control) | 艱製鏇窪製襯製網膚鏇(齋範襯鹽觸糧鹹膚簾壓) = 醖鏇齋願艱選鹹廠淵廠 淵簾範淵壓艱餘繭齋製 (構餘糧窪顧夢繭膚積壓, 簾製鹽範鹽膚壓膚襯願 ~ 遞壓襯鑰網構淵觸憲顧) | ||||||
临床3期 | 235 | 製餘窪繭鑰艱壓餘築願(獵鬱觸觸鏇壓襯築願範) = 衊獵顧廠糧製襯遞醖觸 齋鑰觸範鬱構選鹽築願 (簾遞範築憲顧醖淵鹽襯 ) | - | 2007-08-01 | |||
製餘窪繭鑰艱壓餘築願(獵鬱觸觸鏇壓襯築願範) = 醖顧構遞鑰餘窪鏇網膚 齋鑰觸範鬱構選鹽築願 (簾遞範築憲顧醖淵鹽襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用